Targovax ASA (GB:0RIS) has released an update.
Circio Holding ASA has initiated a rights issue to raise up to NOK 52 million by offering between 3,658,000 to 20,732,010 new shares, with subscription available through the VPS online system until 8 July 2024. The biotech company focuses on developing circular RNA gene therapies and immunotherapy medicines, including a cancer vaccine, TG01, currently undergoing clinical trials. The rights issue details and terms are described in a prospectus available on Circio’s website.
For further insights into GB:0RIS stock, check out TipRanks’ Stock Analysis page.
